Iniparib 是一种不可逆的PARP1抑制剂，在三阴性乳腺 Y 中表现出效力。

Iniparib (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC).

在855-2 细胞中, BSI-201（120 μM） 和buthionine sulfoximine联用可诱导细胞死亡达95%,作用于其他人类肿瘤细胞效果差不多。在E-ras 20 细胞中,BSI-201可抑制细胞生长,与buthionine sulfoximine联用,效果则增强20倍。人淋巴细胞系中,BSI-201（100 μM）可抑制电离辐射诱导的单链断裂 (SSBs) 修复。

Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.(Only for Reference)

160003-66-7

C7H5IN2O3

292.032

NSC-746045;IND-71677;3-硝基-4-碘苯甲酰胺;BSI-201

DMSO:14.6 mg/mL (50 mM)
Ethanol:14.6 mg/mL (50 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years